Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'

Yuri Arcurs | Getty Images Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run. "Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution."

Actions
Connections